within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AE07_Moxifloxacin;

model Moxifloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333334e-10,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 2e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Moxifloxacin</td></tr><tr><td>ATC code:</td><td>S01AE07</td></tr><td>route:</td><td>ocular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.02</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.003</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Moxifloxacin is a fourth-generation fluoroquinolone antibiotic used for the treatment of bacterial infections. It is active against a broad spectrum of Gram-positive and Gram-negative pathogens and is commonly used to treat respiratory tract infections, skin infections, and certain types of conjunctivitis. Moxifloxacin with ATC code S01AE07 refers specifically to its ophthalmological (eye drop) use. The drug is approved for use in many countries and is generally well tolerated.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single and repeated topical ocular administration.</p><h4>References</h4><ol><li><p>Segreti, J, et al., &amp; Bertino, JS (2012). Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 28(1) 3–11. DOI:<a href=\"https://doi.org/10.1089/jop.2011.0072\">10.1089/jop.2011.0072</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21999341/\">https://pubmed.ncbi.nlm.nih.gov/21999341</a></p></li><li><p>Chang, MH, &amp; Fung, HB (2010). Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. <i>Clinical therapeutics</i> 32(3) 454–471. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2010.03.013\">10.1016/j.clinthera.2010.03.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20399984/\">https://pubmed.ncbi.nlm.nih.gov/20399984</a></p></li><li><p>Torkildsen, G, &amp; O&#x27;Brien, TP (2008). Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. <i>Clinical therapeutics</i> 30(11) 2005–2014. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2008.10.020\">10.1016/j.clinthera.2008.10.020</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19108788/\">https://pubmed.ncbi.nlm.nih.gov/19108788</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AE07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Moxifloxacin;
